Genezen Laboratories, Inc. entered into an agreement to acquire Global Manufacturing Facility in Lexington, Massachusetts from uniQure N.V. (NasdaqGS:QURE) for $25 million on July 1, 2024. Total consideration of $25 million, comprised of $12.5 million of newly issued Series C Preferred Stock and a $12.5 million convertible note. Matt Kapusta, chief executive officer of uniQure, will join the Board of Genezen upon the closing of the transaction. Under the proposed transaction, Genezen will be responsible for manufacturing global commercial supply of HEMGENIX® for CSL and providing development and manufacturing services to support uniQure?s investigational gene therapies. uniQure and CSL will be entitled to preferred customer status. The majority of uniQure?s employees at the Lexington facility will be offered employment at Genezen to facilitate a seamless transition. As a result of this transaction, uniQure expects to reduce cash burn by approximately $40 million annually. Upon the closing of the transaction, uniQure anticipates repaying $50 million of outstanding debt, which is expected to yield additional savings in interest expense. Transaction is subject to satisfaction of customary closing conditions and is expected early in the third quarter of 2024.

Leerink Partners LLC acted as financial advisor and Covington & Burling LLP acted as legal advisor for uniQure N.V.